BALB/cmice vaccinated with leishmania major ribosomal proteins extracts combined with CpG oligodeoxynucleotides become resistant to disease caused by a secondary parasite challenge

Journal of Biomedicine and Biotechnology

Volumn 2010, Issue , 2010, Pages

  Ramírez, Laura ^a   Iborra, Salvador ^b   Cortés, Jimena ^a   Bonay, Pedro ^a   Alonso, Carlos ^a   Barral Netto, Manoel ^c   Soto, Manuel ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 4; LEISHMANIA MAJOR RIBOSOMAL PROTEIN; RIBOSOME PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BAGG ALBINO MOUSE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE RESISTANCE; FEMALE; IMMUNITY; INFECTION PREVENTION; LEISHMANIASIS; LYMPH NODE; MOUSE; NONHUMAN; PARASITE LOAD; SECONDARY INFECTION; SPLEEN; TH1 CELL; VACCINATION;

LEISHMANIA MAJOR; MUS;

EID: 84858676742     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2010/181690     Document Type: Article

References (38)

1. B. L. Herwaldt, "Leishmaniasis," Lancet, vol. 354, no. 9185, pp. 1191-1199, 1999. (Pubitemid 29460458)
2. E. Handman, "Leishmaniasis: current status of vaccine development," Clinical Microbiology Reviews, vol. 14, no. 2, pp. 229-243, 2001. (Pubitemid 32294669)
3. S. L. Reiner and R. M. Locksley, "The regulation of immunity to Leishmania major," Annual Review of Immunology, vol. 13, pp. 151-177, 1995.
4. D. Sacks and N. Noben-Trauth, "The immunology of susceptibility and resistance to Leishmania major in mice," Nature Reviews Immunology, vol. 2, no. 11, pp. 845-858, 2002. (Pubitemid 37328707)
5. K. A. Rogers, G. K. DeKrey, M. L. Mbow, R. D. Gillespie, C. I. Brodskyn, and R. G. Titus, "Type 1 and type 2 responses to Leishmania major," FEMS Microbiology Letters, vol. 209, no. 1, pp. 1-7, 2002. (Pubitemid 34457974)
6. R. N. Coler and S. G. Reed, "Second-generation vaccines against leishmaniasis," Trendsin Parasitology , vol. 21, no. 5, pp. 244-249, 2005. (Pubitemid 40544642)
7. C. B. Palatnik-de-Sousa, "Vaccines for leishmaniasis in the fore coming 25 years," Vaccine, vol. 26, no. 14, pp. 1709-1724, 2008.
8. J. Kubar and K. Fragaki, "Recombinant DNA-derived Leish-mania proteins: from the laboratory to the field," Lancet Infectious Diseases, vol. 5, no. 2, pp. 107-114, 2005. (Pubitemid 40174781)
9. M. Soto, L. Ramírez, M. A. Pineda, et al., "Searching genes encoding Leishmania antigens for diagnosis and protection," Scholarly Research Exchange, vol. 2009, Article ID 173039, 2009.
10. J. M. Requena, S. Iborra, J. Carrión, C. Alonso, and M. Soto, "Recent advances in vaccines for leishmaniasis," Expert Opinion on Biological Therapy, vol. 4, no. 9, pp. 1505-1517, 2004. (Pubitemid 39222982)
11. P. A. Bretscher, G. Wei, J. N. Menon, and H. Bielefeldt-Ohmann, "Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major," Science, vol. 257, no. 5069, pp. 539-542, 1992.
12. J. N. Menon and P. A. Bretscher, "Characterization of the immunological memory state generated in mice susceptible to Leishmania major following exposure to low doses of L. major and resulting in resistance to a normally pathogenic challenge," European Journal of Immunology, vol. 26, no. 1, pp. 243-249, 1996.
13. T. M. Doherty and R. L. Coffman, "Leishmania major: effect of infectious dose on T cell subset development in BALB/c mice," Experimental Parasitology, vol. 84, no. 2, pp. 124-135, 1996. (Pubitemid 26399779)
14. J. E. Uzonna, G. Wei, D. Yurkowski, and P. Bretscher, "Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease," Journal of Immunology, vol. 167, no. 12, pp. 6967-6974, 2001. (Pubitemid 33144191)
15. S. Iborra, N. Parody, D. R. Abánades, et al., "Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice," Microbes and Infection, vol. 10, no. 10-11, pp. 1133-1141, 2008.
16. D. L. Sacks, S. Hieny, and A. Sher, "Identification of cell surface carbohydrate and antigenic changes between noninfective and infective developmental stages of Leishmania major promastigotes," Journal of Immunology, vol. 135, no. 1, pp. 564-569, 1985. (Pubitemid 15012427)
17. S. Iborra, J. Carrión, C. Anderson, C. Alonso, D. Sacks, and M. Soto, "Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice," Infection and Immunity, vol. 73, no. 9, pp. 5842-5852, 2005. (Pubitemid 41193021)
18. P. A. Buffet, A. Sulahian, Y. J. F. Garin, N. Nassar, and F. Derouin, "Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice," Antimicrobial Agents and Chemotherapy, vol. 39, no. 9, pp. 2167-2168, 1995.
19. + T cell responses and protection against Leishmania major infection," Journal of Experimental Medicine, vol. 195, no. 12, pp. 1565-1573, 2002. (Pubitemid 34666070)
20. K. J. Stacey and J. M. Blackwell, "Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major," Infection and Immunity, vol. 67, no. 8, pp. 3719-3726, 1999. (Pubitemid 29356983)
21. P. S. Walker, T. Scharton-Kersten, A. M. Krieg, et al., "Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-γ-dependent mechanisms," Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 12, pp. 6970-6975, 1999. (Pubitemid 29274994)
22. D. Sacks and S. Kamhawi, "Molecular aspects of parasitevector and vector-host interactions in leishmaniasis," Annual Review of Microbiology, vol. 55, pp. 453-483, 2001. (Pubitemid 32979159)
23. S. B. H. Ahmed, L. Touihri, Y. Chtourou, K. Dellagi, and C. Bahloul, "DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice," Vaccine, vol. 27, no. 1, pp. 99-106, 2009.
24. Y. Belkaid, S. Kamhawi, G. Modi, et al., "Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis," Journal of Experimental Medicine, vol. 188, no. 10, pp. 1941-1953, 1998. (Pubitemid 28536781)
25. J. Carrión, A. Nieto, M. Soto, and C. Alonso, "Adoptive transfer of dendritic cells pulsed with Leishmania infantum nucleosomal histones confers protection against cutaneous leishmaniosis in BALB/c mice," Microbes and Infection, vol. 9, no. 6, pp. 735-743, 2007. (Pubitemid 46660686)
26. N. Courret, T. Lang, G. Milon, and J.-C. Antoine, "Intradermal inoculations of low doses of Leishmania major and Leish-mania amazonensis metacyclic promastigotes induce different immunoparasitic processes and status of protection in BALB/c mice," International Journal for Parasitology, vol. 33, no. 12, pp. 1373-1383, 2003. (Pubitemid 37176982)
27. + regulatory T cells in reactivation of persistent leishmaniasis and control of concomitant immunity," Journal of Experimental Medicine, vol. 200, no. 2, pp. 201-210, 2004. (Pubitemid 38982179)
28. I. Muller, "Role of T cell subsets during the recall of immuno-logic memory to Leishmania major," European Journal of Immunology, vol. 22, no. 12, pp. 3063-3069, 1992.
29. M. M. Kane and D. M. Mosser, "The role of IL-10 in promoting disease progression in leishmaniasis," Journal of Immunology, vol. 166, no. 2, pp. 1141-1147, 2001. (Pubitemid 32060273)
30. K. W. Moore, R. de Waal Malefyt, R. L. Coffman, and A. O'Garra, "Interleukin-10 and the interleukin-10 receptor," Annual Review of Immunology, vol. 19, pp. 683-765, 2001. (Pubitemid 32368050)
31. N. Noben-Trauth, "Susceptibility to Leishmania major infection in the absence of IL-4," Immunology Letters, vol. 75, no. 1, pp. 41-44, 2000.
32. N. Noben-Trauth, R. Lira, H. Nagase, W. E. Paul, and D. L. Sacks, "The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major," Journal of Immunology, vol. 170, no. 10, pp. 5152-5158, 2003. (Pubitemid 36554747)
33. J. Carrión, C. Folgueira, and C. Alonso, "Transitory or long-lasting immunity to Leishmania major infection: the result of immunogenicity and multicomponent properties of histone DNA vaccines," Vaccine, vol. 26, no. 9, pp. 1155-1165, 2008.
34. R. L. Coffman, "Mechanisms of helper T cell regulation of B-cell activity," Annals of the New York Academy of Sciences, vol. 681, pp. 25-28, 1993. (Pubitemid 23233802)
35. T. M. Doherty and R. L. Coffman, "Leishmania antigens presented by GM-CSF-derived macrophages protect susceptible mice against challenge with Leishmania major," Journal of Immunology, vol. 150, no. 12, pp. 5476-5483, 1993. (Pubitemid 23180661)
36. + regulatory T cells control Leishmania major persistence and immunity," Nature, vol. 420, no. 6915, pp. 502-507, 2002. (Pubitemid 35477041)
37. C. L. Greenblatt, "The present and future of vaccination for cutaneous leishmaniasis," Progress in Clinical and Biological Research, vol. 47, pp. 259-285, 1980.
38. S. Méndez, S. Gurunathan, S. Kamhawi, et al., "The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge," Journal of Immunology, vol. 166, no. 8, pp. 5122-5128, 2001. (Pubitemid 32280726)